Agile Therapeutics Balance Sheet - Annual (NASDAQ:AGRX)

Add to My Stocks
$2.93 $0.03 (1.03%) AGRX stock closing price Mar 22, 2018 (Closing)

The fundamental analysis of this company requires a thorough look at Agile Therapeutics balance sheet. As in our Agile Therapeutics stock analysis, analyzing a company also involves looking at the company's assets and liabilities as given in its balance sheet, which can be used to measure financial performance. A company releases its balance sheet every year along with its annual results. Agile Therapeutics had a long term debt of $10.89M at the end of 2016. To understand the debt servicing capacity of the company, one needs to look at Agile Therapeutics operating cash flow and Agile Therapeutics revenue also. Agile Therapeutics debt to equity ratio is .

View latest 10 year balance sheet data to check Agile Therapeutics financial performance.
show more
Fiscal year is Jan - Dec20162015201420132012
Marketable Securities-----
Raw Materials-----
Work In Progress-----
Finished Goods-----
Notes Receivable-----
Other Current Assets2.76M3.69M---
Total Current Assets
Property Plant & Equipment12.65M12.62M12.33M12.23M7.29M
Accumulated Depreciation-----
Net Property Plant & Equipment
Investment & Advances-----
Other Non-Current Assets-----
Deferred Charges-----
Deposits & Other Assets--1.69M--
Total Assets
Notes Payable-----
Accounts Payable2.05M2.38M2.63M-1.12M
Current Portion Long-Term Debt-----
Current Portion Capital Leases-----
Accrued Expenses3.35M2.65M1.06M--
Income Taxes Payable-----
Other Current Liabilities5.27M2.89M5.29M5.74M-
Total Current Liabilities
Deferred Taxes/Income-----
Convertible Debt-----
Long-Term Debt10.89M13.03M9.82M9.76M14.78M
Non-Current Capital Leases-----
Other Long-Term Liabilities-----
Total Liabilities
Minority Interest---69.23M69.23M
Preferred Stock-----
Common Stock Net-----
Capital Surplus235.75M194.46M170.39M46.87M45.38M
Retained Earnings-193.46M-164.72M-134.39M-118.31M-103.99M
Treasury Stock-----
Other Liabilities-----
Shareholders Equity42.28M29.74M36M-71.44M-58.6M
Total Liabilities & Shareholders Equity63.86M50.71M54.82M14.4M27.51M
All figures in USD. M: Millions of USD, B: Billions of USD.

Most investors just check the Agile Therapeutics stock price, and Agile Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Agile Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: AGRX total assets, which was at $63.86M for 2016 is a balance sheet item representing value of what Agile Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. AGRX stock had total liabilities of $21.57M for the year 2016.

Agile Therapeutics Balance Sheet - Key Ratios